Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 22386420)

1.

Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.

Rhodes T, Jacobson DJ, McGree ME, St Sauver JL, Girman CJ, Lieber MM, Klee GG, Demissie K, Jacobsen SJ.

Urology. 2012 Mar;79(3):655-61. doi: 10.1016/j.urology.2011.09.056.

2.

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

Khan MA, Sokoll LJ, Chan DW, Mangold LA, Mohr P, Mikolajczyk SD, Linton HJ, Evans CL, Rittenhouse HG, Partin AW.

Urology. 2004 Dec;64(6):1160-4.

PMID:
15596190
3.

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.

Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW.

J Urol. 2003 Sep;170(3):723-6.

PMID:
12913682
4.

Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study.

Jacobsen SJ, Jacobson DJ, McGree ME, St Sauver JL, Klee GG, Girman CJ, Lieber MM.

Mayo Clin Proc. 2012 Jan;87(1):34-40. doi: 10.1016/j.mayocp.2011.09.002.

5.

Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.

St Sauver JL, Jacobson DJ, Girman CJ, Lieber MM, McGree ME, Jacobsen SJ.

J Urol. 2006 Mar;175(3 Pt 1):1018-22; discussion 1022.

PMID:
16469608
6.

Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.

Mikolajczyk SD, Rittenhouse HG.

Rinsho Byori. 2004 Mar;52(3):223-30. Review.

PMID:
15137320
7.

Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.

Filella X, Alcover J, Molina R, Luque P, Corral JM, Augé JM, Coca F.

Anticancer Res. 2007 Jan-Feb;27(1B):607-10.

8.

Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men.

Rhodes T, Jacobson DJ, McGree ME, St Sauver JL, Sarma AV, Girman CJ, Lieber MM, Klee GG, Demissie K, Jacobsen SJ.

J Urol. 2012 Jan;187(1):87-91. doi: 10.1016/j.juro.2011.09.061. Epub 2011 Nov 16.

9.
10.

Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.

Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.

Urology. 2004 Mar;63(3):492-8.

PMID:
15028444
11.

The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection.

Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, Sarma AV.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):501-8. doi: 10.1158/1055-9965.EPI-10-1006. Epub 2011 Jan 17.

12.

Predictive properties of serum-prostate-specific antigen testing in a community-based setting.

Jacobsen SJ, Bergstralh EJ, Guess HA, Katusic SK, Klee GG, Oesterling JE, Lieber MM.

Arch Intern Med. 1996 Nov 25;156(21):2462-8.

PMID:
8944739
13.

Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.

Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW.

Clin Cancer Res. 2009 Dec 1;15(23):7316-21. doi: 10.1158/1078-0432.CCR-09-1263. Epub 2009 Nov 24.

14.

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.

Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM.

Urology. 2004 May;63(5):905-10; discussion 910-1.

PMID:
15134977
15.

Longitudinal changes in peak urinary flow rates in a community based cohort.

Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM.

J Urol. 2000 Jan;163(1):107-13.

PMID:
10604326
16.

Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men.

Rhodes T, Jacobson DJ, McGree ME, St Sauver JL, Sarma AV, Girman CJ, Lieber MM, Klee GG, Demissie K, Jacobsen SJ.

J Urol. 2012 Jan;187(1):92-6. doi: 10.1016/j.juro.2011.09.060. Epub 2011 Nov 16.

17.

Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan D, Carter H.

J Urol. 2002 Jun;167(6):2484-7; discussion 2487-8.

PMID:
11992063
18.

Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men's Health Study.

Sarma AV, St Sauver JL, Jacobson DJ, McGree ME, Klee GG, Lieber MM, Girman CJ, Hollingsworth JM, Jacobsen SJ; Urologic Diseases in America Project.

Urology. 2014 Jan;83(1):88-93. doi: 10.1016/j.urology.2013.08.025. Epub 2013 Oct 16.

19.

Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.

Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD.

Clin Chem. 2003 Feb;49(2):253-9.

20.

Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times.

Lieber MM, Rhodes T, Jacobson DJ, McGree ME, Girman CJ, Jacobsen SJ, St Sauver JL.

BJU Int. 2010 Jan;105(2):214-9. doi: 10.1111/j.1464-410X.2009.08719.x. Epub 2009 Jul 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk